|1.||Lee, F Y: 1 article (01/2000)|
|2.||Kadow, J: 1 article (01/2000)|
|3.||Rose, W C: 1 article (01/2000)|
|4.||Golik, J: 1 article (01/2000)|
01/01/1997 - "In each of the tumor models used, the consistently active, and usually the most active, water-soluble derivative was BMS-185660. "
01/01/1997 - "Based on the evaluations performed in three distal site tumor models, we conclude that BMS-185660 is a water-soluble paclitaxel derivative with preclinical antitumor activity comparable to that of the parent drug."
01/01/2000 - "Against a human ovarian tumor model with developed resistance to cisplatin (A2780/ cDDP), oral BMS-185660 achieved a maximum LCK of 1.8 compared with i.v. paclitaxel, which produced a maximum 2.4 LCK. "